Cargando…

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer

Introduction: It is still controversial whether post-mastectomy radiotherapy (PMRT) is necessary for women with T1-2 N1mic ER-positive HER2-negative breast cancer. The 21-gene recurrence score (RS) assay has been validated in T1-2 N1 breast cancer to be prognostic of locoregional recurrence (LRR) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wen-Wen, Tong, Qin, Sun, Jia-Yuan, Hua, Xin, Long, Zhi-Qing, Deng, Jia-Peng, Dong, Yong, Li, Feng-Yan, He, Zhen-Yu, Wu, San-Gang, Lin, Huan-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477026/ https://www.ncbi.nlm.nih.gov/pubmed/31041190 http://dx.doi.org/10.3389/fonc.2019.00270

Ejemplares similares

The Effect of Post-mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: An Analysis of SEER Database
por: Wang, Jun, et al.
Publicado: (2019)

Long-term survival effect of the interval between mastectomy and radiotherapy in locally advanced breast cancer
por: Zhang, Wen-Wen, et al.
Publicado: (2018)

Efficacy of post‑mastectomy radiotherapy in patients with T1‑2N1 breast cancer aged ≤35 years or with a positive HER‑2 status
por: Wang, Mincong, et al.
Publicado: (2023)

Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy
por: Chen, Chu-Ying, et al.
Publicado: (2022)

The effect of post mastectomy radiation therapy on survival in breast cancer patients with N1mic disease
por: Patel, Mausam, et al.
Publicado: (2020)

MIC1 and MIC3: partners in invasion
por: Van Epps, Heather L.
Publicado: (2005)

Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1–2 tumor and 1–3 axillary lymph node(s) metastasis
por: Su, Yu-Li, et al.
Publicado: (2014)

Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
por: Jwa, Eunjin, et al.
Publicado: (2015)

The Value of Prognostic Nutritional Index (PNI) in Predicting Survival and Guiding Radiotherapy of Patients With T1-2N1 Breast Cancer
por: Hua, Xin, et al.
Publicado: (2020)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
por: Lefort, S, et al.
Publicado: (2017)

Comparison of survival outcomes of locally advanced breast cancer patients receiving post-mastectomy radiotherapy with and without immediate breast reconstruction: a population-based analysis
por: Wu, San-Gang, et al.
Publicado: (2018)

Development and validation of nomograms for predicting survival outcomes in patients with T1-2N1 breast cancer to identify those who could not benefit from postmastectomy radiotherapy
por: Pu, Hongyu, et al.
Publicado: (2023)

Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine
por: Fazekas, Judit, et al.
Publicado: (2016)

Structural insights into MIC2 recognition by MIC2-associated protein in Toxoplasma gondii
por: Zhang, Su, et al.
Publicado: (2023)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
por: He, Lin, et al.
Publicado: (2019)

T1-2N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy
por: Wang, Xueying, et al.
Publicado: (2020)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
por: Sun, Guang-Yi, et al.
Publicado: (2021)

Erratum to prognostic value of skeletal muscle index and monocyte-to-lymphocyte ratio for lymph node-positive breast cancer patients after mastectomy
por: Deng, Jia-Peng, et al.
Publicado: (2020)

A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy
por: Chen, Kai, et al.
Publicado: (2022)

Receptor Heterodimerization and Co-Receptor Engagement in TLR2 Activation Induced by MIC1 and MIC4 from Toxoplasma gondii
por: Costa Mendonça-Natividade, Flávia, et al.
Publicado: (2019)

Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients
por: Chen, Zhi, et al.
Publicado: (2022)

Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes
por: He, Zhen-Yu, et al.
Publicado: (2015)

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application
por: Laas, Enora, et al.
Publicado: (2016)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Skin-sparing mastectomy and radiotherapy: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Lymph node ratio may predict the benefit of postoperative radiotherapy in node-positive cervical cancer
por: Zhou, Juan, et al.
Publicado: (2016)

Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study
por: Li, Zhi-wen, et al.
Publicado: (2020)

Dosimetric analysis of the brachial plexus among patients with breast cancer treated with post-mastectomy radiotherapy to the ipsilateral supraclavicular area: report of 3 cases of radiation-induced brachial plexus neuropathy
por: Wu, San-Gang, et al.
Publicado: (2014)

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
por: Wang, Xiaofang, et al.
Publicado: (2021)

Correction: Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes
por: He, Zhen-Yu, et al.
Publicado: (2015)

Utility of post mastectomy radiotherapy among patients with T1/ T2 N1 disease: A retrospective cohort study
por: Vohra, Lubna M., et al.
Publicado: (2021)

The Role of Post-Mastectomy Radiotherapy in T1-2N1 Breast Cancer Patients: Propensity Score Matched Analysis
por: Kim, Kangpyo, et al.
Publicado: (2023)

Evaluation of the immune protective effects of rEmMIC2 and rEmMIC3 from Eimeria magna in rabbits
por: Chen, Hao, et al.
Publicado: (2022)

Open Mic - Programming meetup #2
por: Schovancova, Jaroslava
Publicado: (2018)

Open mic: CMS Create #2
por: Koutava, Ioanna
Publicado: (2016)

The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer
por: Zhang, Lei, et al.
Publicado: (2020)

Could patients benefit from whole-brain radiotherapy with unilateral hippocampus sparing?
por: Sapienza, Lucas Gomes, et al.
Publicado: (2021)

Post-Mastectomy Radiotherapy for Breast Cancer Patients with T1-T2 and 1-3 Positive Lymph Nodes: a Meta-Analysis
por: Li, Yaming, et al.
Publicado: (2013)

Her2 positivity and race predict higher mastectomy rates: a SEER database analysis
por: Schwartz, Theresa L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_833k9auk7pqq09610nbi0s3f3e